Prognostic Value of Fluorine-19 MRI Oximetry Monitoring in cancer

Fanny Chapelin; Roberto Gedaly; Zachary Sweeney; Liza J. Gossett

doi:10.1007/s11307-021-01648-3

Prognostic Value of Fluorine-19 MRI Oximetry Monitoring in cancer

Fanny Chapelin, Roberto Gedaly, Zachary Sweeney, Liza J. Gossett

Research output: Contribution to journal › Review article › peer-review

Abstract

Hypoxia is a key prognostic indicator in most solid tumors, as it is correlated to tumor angiogenesis, metastasis, recurrence, and response to therapy. Accurate measurement and mapping of tumor oxygenation profile and changes upon intervention could facilitate disease progression assessment and assist in treatment planning. Currently, no gold standard exists for non-invasive spatiotemporal measurement of hypoxia. Magnetic resonance imaging (MRI) represents an attractive option as it is a clinically available and non-ionizing imaging modality. Specifically, perfluorocarbon (PFC) beacons can be externally introduced into the tumor tissue and the linear dependence of their spin-lattice relaxation rate (R1) on the local partial pressure of oxygen (pO₂) exploited for real-time tissue oxygenation monitoring in vivo. In this review, we will focus on early studies and recent developments of fluorine-19 MRI and spectroscopy (MRS) for evaluation of tumor oximetry and response to therapy.

Original language	English
Pages (from-to)	208-219
Number of pages	12
Journal	Molecular Imaging and Biology
Volume	24
Issue number	2
DOIs	https://doi.org/10.1007/s11307-021-01648-3
State	Published - Apr 2022

Bibliographical note

Funding Information:
This publication was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR001998, the American Cancer Society Grant IRG-19-140-31 and by the University of Kentucky Lucille P. Markey Cancer Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Publisher Copyright:
© 2021, World Molecular Imaging Society.

Keywords

Cancer
Fluorine-19 (F)
Hypoxia
MRI
Oximetry
Perfluorocarbon (PFC)

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11307-021-01648-3

Cite this

@article{fee93a09f04244e9997d28c13794f122,

title = "Prognostic Value of Fluorine-19 MRI Oximetry Monitoring in cancer",

abstract = "Hypoxia is a key prognostic indicator in most solid tumors, as it is correlated to tumor angiogenesis, metastasis, recurrence, and response to therapy. Accurate measurement and mapping of tumor oxygenation profile and changes upon intervention could facilitate disease progression assessment and assist in treatment planning. Currently, no gold standard exists for non-invasive spatiotemporal measurement of hypoxia. Magnetic resonance imaging (MRI) represents an attractive option as it is a clinically available and non-ionizing imaging modality. Specifically, perfluorocarbon (PFC) beacons can be externally introduced into the tumor tissue and the linear dependence of their spin-lattice relaxation rate (R1) on the local partial pressure of oxygen (pO2) exploited for real-time tissue oxygenation monitoring in vivo. In this review, we will focus on early studies and recent developments of fluorine-19 MRI and spectroscopy (MRS) for evaluation of tumor oximetry and response to therapy.",

keywords = "Cancer, Fluorine-19 (F), Hypoxia, MRI, Oximetry, Perfluorocarbon (PFC)",

author = "Fanny Chapelin and Roberto Gedaly and Zachary Sweeney and Gossett, {Liza J.}",

note = "Funding Information: This publication was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR001998, the American Cancer Society Grant IRG-19-140-31 and by the University of Kentucky Lucille P. Markey Cancer Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Publisher Copyright: {\textcopyright} 2021, World Molecular Imaging Society.",

year = "2022",

month = apr,

doi = "10.1007/s11307-021-01648-3",

language = "English",

volume = "24",

pages = "208--219",

number = "2",

}

TY - JOUR

T1 - Prognostic Value of Fluorine-19 MRI Oximetry Monitoring in cancer

AU - Chapelin, Fanny

AU - Gedaly, Roberto

AU - Sweeney, Zachary

AU - Gossett, Liza J.

N1 - Funding Information: This publication was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR001998, the American Cancer Society Grant IRG-19-140-31 and by the University of Kentucky Lucille P. Markey Cancer Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Publisher Copyright: © 2021, World Molecular Imaging Society.

PY - 2022/4

Y1 - 2022/4

N2 - Hypoxia is a key prognostic indicator in most solid tumors, as it is correlated to tumor angiogenesis, metastasis, recurrence, and response to therapy. Accurate measurement and mapping of tumor oxygenation profile and changes upon intervention could facilitate disease progression assessment and assist in treatment planning. Currently, no gold standard exists for non-invasive spatiotemporal measurement of hypoxia. Magnetic resonance imaging (MRI) represents an attractive option as it is a clinically available and non-ionizing imaging modality. Specifically, perfluorocarbon (PFC) beacons can be externally introduced into the tumor tissue and the linear dependence of their spin-lattice relaxation rate (R1) on the local partial pressure of oxygen (pO2) exploited for real-time tissue oxygenation monitoring in vivo. In this review, we will focus on early studies and recent developments of fluorine-19 MRI and spectroscopy (MRS) for evaluation of tumor oximetry and response to therapy.

AB - Hypoxia is a key prognostic indicator in most solid tumors, as it is correlated to tumor angiogenesis, metastasis, recurrence, and response to therapy. Accurate measurement and mapping of tumor oxygenation profile and changes upon intervention could facilitate disease progression assessment and assist in treatment planning. Currently, no gold standard exists for non-invasive spatiotemporal measurement of hypoxia. Magnetic resonance imaging (MRI) represents an attractive option as it is a clinically available and non-ionizing imaging modality. Specifically, perfluorocarbon (PFC) beacons can be externally introduced into the tumor tissue and the linear dependence of their spin-lattice relaxation rate (R1) on the local partial pressure of oxygen (pO2) exploited for real-time tissue oxygenation monitoring in vivo. In this review, we will focus on early studies and recent developments of fluorine-19 MRI and spectroscopy (MRS) for evaluation of tumor oximetry and response to therapy.

KW - Cancer

KW - Fluorine-19 (F)

KW - Hypoxia

KW - MRI

KW - Oximetry

KW - Perfluorocarbon (PFC)

UR - http://www.scopus.com/inward/record.url?scp=85117904881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85117904881&partnerID=8YFLogxK

U2 - 10.1007/s11307-021-01648-3

DO - 10.1007/s11307-021-01648-3

M3 - Review article

C2 - 34708396

AN - SCOPUS:85117904881

VL - 24

SP - 208

EP - 219

IS - 2

ER -

Prognostic Value of Fluorine-19 MRI Oximetry Monitoring in cancer

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this